Glioblastoma, the most aggressive primary brain tumor, thrives in a microenvironment of relative immunosuppression within the relatively immune-privileged central nervous system. Despite treatments with surgery, radiation therapy, and chemotherapy, prognosis remains poor. The recent success of immunotherapy in the treatment of other cancers has renewed interest in vaccine therapy for the treatment of gliomas. In this article, we outline various immunotherapeutic strategies, review recent clinical trials data, and discuss the future of vaccine therapy for glioblastoma.
G lioblastoma, the most frequent and malignant primary brain tumor, stands apart from other neoplasms by its biology and location within the central nervous system (CNS). Despite aggressive multimodal treatment including surgical resection, radiation therapy, and cytotoxic chemotherapy, the disease remains incurable with a median survival under 15 months and a 2-year survival of 26.5%. 1 The failure of conventional oncological treatment to selectively eradicate glioblastoma cells has prompted investigators to look for new and more targeted therapeutic options as well as for improved prognostic biomarkers that will help us better understand the variation of outcomes.
Immunotherapy offers a different mechanistic approach from chemotherapy, targeted therapy, radiation and surgery, and its recent success in the treatment of other cancers has fueled a resurgence of interest in this approach. Currently, there are 17 U.S. Food and Drug AdministrationYapproved immunologic products used in the treatment of human malignancies. 2 Most of the available immunologic treatments are antibody-based therapies; however, in 2011, the first cell-based therapy was approved for the treatment of prostate cancer, opening the door for other immunologic approaches. In the case of gliomas, there are several tumor vaccine strategies that have been explored in clinical trials. Although the initial results are encouraging, the small noncontrolled studies preclude definitive proof of improvement in survival.
In this article, we will give a brief overview of the immune system and its relation to the nervous system and cancer, as it provides the rationale for the use of immunotherapy in brain tumors. We will discuss promising immune-based therapies, focusing on the outcomes and limitations of ongoing clinical trials that employ vaccines to treat patients with glioblastoma. Finally, we focus on strategies that could refine these vaccine approaches to enhance the potential benefits and become part of the conventional armamentarium to fight glioblastoma.
OVERVIEW OF THE IMMUNE SYSTEM
The primary role of the immune system is to discriminate between self and nonself to recognize foreign invaders and defend against them. The immune system can be divided into 2 main branches: the innate and the adaptive immune systems. 3, 4 The innate immune system, the first line of defense, recognizes pathogen-associated molecular patterns, or PAMPs, via engagement of Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs), which are present before an infection takes hold. The innate immune system consists of macrophages, monocytes, neutrophils, natural killer (NK) cells, basophils, eosinophils, and complement. The adaptive immune system, by contrast, must be activated by antigens. The adaptive immune system consists of T and B lymphocytes, and antigen-presenting cells (APCs). T cells, so-named because they mature in the thymus, fall into 2 large subcategories of cytotoxic T cells and helper T cells. The cytotoxic T cells express CD8 receptor that binds to antigens presented in the context of human leukocyte antigen (HLA) major histocompatibility complex (MHC) class I molecules, and along with a second signal mediated by CD28 binding to its ligand B7, leads to cell-mediated killing. The CD4+ helper T cells bind to antigens presented on HLA MHC class II molecules. The CD4+/MHC class II interaction leads to cytokine release and recruitment of other immune cells. By contrast, B cells mature in the bone marrow and are involved in production of antibody and antibody-dependent cell-mediated cytotoxicity. Once they see antigen, B cells mature into plasmatic cells that secrete antibodies that then bind to antigens. The antigen-antibody complex signals immune detection and triggers killing by a variety of cells including NK cells.
The most active APCs are dendritic cells (DCs) that reside as immature cells in almost every organ and tissue, 5 sit at the interface of pathogen entry sites and continuously sample antigens. Antigen sampling results in effective antigen presentation when the DCs are triggered by other ''danger signals.'' ''Danger signals'' are signs of tissue damage or inflammation. 5 Dangertriggered DCs start to mature and become activated. Activated DCs up-regulate their chemokine receptors, allowing trafficking to lymph nodes where they can induce T-cell responses ( Fig. 1 ).
to brake immune activation is regulatory T cells (Tregs), which were first proposed in 1972 6 and discovered in 1995. 7 They are now recognized as a key regulatory pathway in tumor tolerance and have a unique cell surface signature, with expression of both CD4 and CD25 (the alpha chain of the interleukin 2 [IL-2] receptor). 7 These cells express other cell surface markers, including CTLA4 8 and glucocorticoid-induced tumor necrosis factor receptor, 9 and are regulated by a transcription factor called forkhead box protein 3 (FOXP3). 10 Tregs actively inhibit conventional CD4+ T cells, CD8+ T cells, DCs, and NK cells, 11 thus dampening immune responses. Other immune regulatory pathways such as immune-suppressive cytokines, myeloid-derived suppressor cells, regulatory B cells, and NK cells also play important roles in generating and maintaining tumor tolerance and, along with Tregs, are considered targets of immune therapy 12, 13 ( Fig. 1 ).
NEUROIMMUNOLOGY
It was once thought that the nervous system was an immune privileged organ, devoid of normal immunologic function. 3, 14, 15 The CNS features in support of this theory included the bloodbrain barrier that allows for selective entry of immune cells from the peripheral blood into the brain parenchyma, the lack of lymphatic vessels and lymph nodes within the CNS, and the low numbers of circulating T cells in the CNS. Furthermore, there is less HLA presentation and absence of traditional APCs in the CNS when compared with other tissues. Nevertheless, under physiologic conditions, the brain hosts several populations of immune cells. 15 Microglia arise from hematopoietic cells and colonize CNS during embryonic development. The microglia constitutes an early line of defense for the brain. Microglial cells migrate to inflammatory zones in the CNS and become activated. Once activated, they have phagocytic and APC properties, as well as the ability to recruit other immune cells by secreting cytokines and chemokines. 16 Macrophages and DCs both arise from monocytes. They are found in perivascular zones, choroid plexus, and meninges. Because of their role as professional APCs, DC-based vaccine therapy has been the most studied approach for high-grade gliomas. T cells are found in the CNS only in the activated form. Naive T cells are not present in the CNS. 17, 18 T cells are activated in cervical lymph nodes and then move into the CNS. It is unclear how antigens are transported from the brain to the cervical nodes to activate the T cells.
Cancer immunotherapy has unique challenges in the CNS due to the relative immune privilege of the brain and the immune suppression caused by high-grade gliomas. The bloodbrain barrier, low numbers of T lymphocytes, and lack of a lymphatic systems make it challenging for immune cells to enter the CNS. In patients with glioblastoma, the blood-brain barrier is disorganized. 15, 19 Tissue injury leads to breakdown of the tight junctions between endothelial cells that facilitate migration of leukocytes into the CNS. Although the CNS is devoid of traditional lymphatic vessels, CSF drains via Virchow-Robin spaces to the deep cervical lymphatics. 17, 20 T cells located in the cervical lymph nodes are activated and can patrol the CNS. 17, 18 Activated T cells that encounter their antigen are retained in the CNS. HLA presentation occurs on astrocytes, microglia, and endothelial cells. 3, 14 The net balance is that CNS immune surveillance still occurs. 3 Patients with glioblastoma exhibit a relative systemic immune suppression compared with the general population. Adaptive immune responses are deficient. 17 The tumor microenvironment is rich with immunosuppressive factors secreted by the tumor, 17 like transforming growth factor beta (TGF-A) and vascular endothelial growth factor (VEGF) that suppresses T-cell proliferation and cytotoxic function. 21, 22 VEGF inhibits the maturation of DCs. In glioma patients, there are diminished absolute counts of CD4+ T cells with increased fraction of Tregs. 3, 23 This immunosuppression likely plays an important role in tumor progression in patients with glioblastoma. In addition to being immunosuppressed from having a malignancy, 
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RATIONALE FOR IMMUNOTHERAPY
It has been long observed that changes in the immune system relate to cancer survival. Neurologists and neurosurgeons provide anecdotal reports that glioma patients who experience postoperative infections near the tumor bed seem to do better than the average patient similar to the observations made over a century ago by Coley. 24 Recently, De Bonis et al 25 investigated the idea that postoperative infection may confer a survival advantage to patients with malignant glioma. They reviewed 197 cases of newly diagnosed glioblastoma, 10 of whom had perioperative infections. The infection group had a significant advantage in the median survival; 30 months compared to 15 months in the noninfected tumor patients. We now understand that infection can contribute to activation of immune pathways via PAMPs and activation of TLR on the innate immune system and subsequently initiate anti-tumor immunity. Indeed, a direct correlation between survival of patients with primary glioblastoma and tumor infiltration of cytotoxic and helper T cells has been observed. 26 As noted previously, glioblastoma patients are relatively immunosuppressed compared to the general population. The degree of immunosuppression also correlates with survival. Grossman et al 27 recently followed a group of 96 patients with newly diagnosed high-grade gliomas through surgery, radiation therapy, and chemotherapy with temozolomide. The patients had a normal CD4+ count at diagnosis but hit a nadir 2 months after treatment. Forty percent of the study population had CD4+ counts of less than 200/KL, and those patients had a significantly shorter median survival at 13.1 months compared with 19.7 months in patients with higher counts. All of these observations taken together suggest that, if the immune effectors were better activated in glioblastoma, patients might have better outcomes.
STRATEGIES FOR USING IMMUNOTHERAPY IN THE TREATMENT OF GLIOMAS
As with immunization for infections, immunization against tumors can theoretically occur in the form of passive or active immunotherapy. 15 In passive immunotherapy, a patient is given immune cells or antibodies capable of targeting the tumor cell. Passive immunotherapy does not require activation of the patient's own immune system, but instead immune cells are active in vitro and injected into the patient. By contrast, active immunotherapy provides a boost to the patient's native immune system ( Fig. 3) .
In broad terms, passive immunotherapy can be further divided into 3 approaches 5 (Fig. 3 ). The first is the direct injection of monoclonal antibodies. 2, 3 In this approach, antibodies that are known to interact with an antigen specific to or associated with a tumor are administered to the patient. In glioblastoma, only 1 monoclonal antibody has been approved for treatment. Bevacizumab is a humanized IgG1 monoclonal antibody that binds to and neutralizes the VEGF ligand. 2, 28, 29 VEGF is a tumor-associated protein, which is found on a variety of malignancies, including glioblastoma. VEGF is the central mediator of tumor angiogenesis. Although bevacizumab retains its ability to bind complement and Fc receptor, its action is through blocking the ligand that activates the VEGF receptor on tumor blood vessels thereby inhibiting angiogenesis and tumor growth. Bevacizumab may also be associated with afferent vascular dilatation and efferent vascular constriction of tumor vessels. This may give the additional benefit of concentrating chemotherapy at the tumor site.
The second approach to cancer passive immunotherapy is to stimulate the immune system with cytokines. Cytokine stimulation with IL-2 have been studied in a variety of cancers, and although it has been a successful approach in melanoma and renal cell cancer, it has not shown benefit in glioblastoma. 2 A third strategy to passive immunotherapy is treatment with stimulated immune effector cells. This approach has also been called adoptive immunity or cell-based therapy immunotherapy. 15 In adoptive immunity, immune cells activated ex vivo are administrated to patient, either by systemic injection or directly into the tumor or tumor resection cavity. Both lymphocyteactivated killer (LAK) cells and CTLs have been used. LAK cells are generally obtained by cultivating autologous peripheral lymphocytes in the presence of IL-2. The culture yields both T and NK cells. The immune reaction provided by LAK cells is nonspecific cytotoxicity, which is not necessarily tumor directed. By contrast, CTLs are prepared by collecting peripheral blood mononuclear cells or tumor-infiltrating lymphocytes and then stimulating them ex vivo with antigens. For cancer immunotherapy, autologous tumor cells are also used for the antigen stimulation, thus yielding CTLs that have been activated with specificity to the tumor.
Active immunotherapy boosts the patient's immune system by priming it with antigen exposure. There are 2 approaches to active immunization: peptide-based therapy and cell-based therapy 30 (Fig. 3) . In peptide-based therapy, peptides are injected as a vaccine to induce immune activation. Tumors express various antigens, some of which are tumor specific and others that are tumor associated. Tumor antigens can be also categorized as cancer testes antigens, tumor differentiation antigens, viralrelated antigens, or mutated oncogenic proteins. The peptides selected for cancer vaccines are typically small, around 9 amino acids in length, and are capable of binding to MHC class I molecules, which leads to activation of CTL.
Cell-based active immunotherapy uses APCs activated by tumor antigens to prime the immune system rather than the antigen itself. Because DCs are professional APCs, they are an obvious choice for active immunotherapy and have to date been the most studied cell-based vaccine. 5, 15, 30 In most cases, DCs are prepared from autologous peripheral blood mononuclear cells and are cultivated in the presence of growth factors, such as granulocyte macrophage colony stimulating factor (GM-CSF) and interleukin 4. The DCs are then matured and activated by antigens, which can be prepared from various sources, including tumor lysates, peptides eluded from activated tumor cells, defined peptides such as those used in peptide-based immunotherapy, viral antigens, mRNA derived from activated tumor cells, and whole tumor cells. The activated DCs are then given back to the patient, either injected intradermally in the lymph nodes or locally at the tumor site.
CLINICAL REPORTS OF IMMUNOTHERAPY
Interpretation and comparison of the results of clinical trials using immune therapy against glioblastoma is extremely difficult because of heterogeneity in study design, therapeutic approach used, immune endpoints measured, and patient eligibility criteria. The classic design of cancer clinical trials does not fit the immune therapy model. For example, although most vaccine trials are phase I, the ''dose escalation'' design does not apply because treatments usually have minimal toxicity; the dose limitation is the availability of cells and not the appearance of adverse events. 17 The few phase II clinical trials published are not randomized and use historic controls to compare outcomes. Most clinical trials included patients with recurrent glioblastoma, who may have a poor functional status, large tumor burden, and been heavily pretreated making less likely to benefit of immune therapy. In the clinical trials, there are exclusion criteria that render a highly selected population of evaluable patient. 31 Furthermore, some trials include patients with newly diagnosed and recurrent disease and, on occasions, include patients with anaplastic gliomas. Surrogate endpoints, like immunologic assays and brain imaging studies, have not been harmonized and validated in most cases.
Passive Immunotherapy
The earliest attempts at immune therapy in the late 1980s into the 1990s focused on passive immunization by infusion of LAK cells directly into the tumor bed in the perioperative and postoperative period. 32Y38 Adverse effects from this strategy included cerebral edema, increased intracranial pressure, headaches, fever, and confusion, 32, 36 but in general, the treatment was well tolerated. In most instances, there was no impact on survival, 32, 34, 36, 37 although Hayes et al 38Y41 and others suggested an improved median survival compared with contemporary controls in patients with recurrent glioblastoma treated with LAK cells and IL-2.
In addition to LAK cells, CTLs are the other group of cells studied in adoptive immune responses for glioblastoma. 42Y50 The first study of CTLs was by Kitahara et al 48 
Active Immunotherapy
In the realm of active immunity, both cell-based therapies and peptide-based therapies have been studied. Patients have be given individual peptides, 52, 53, 58 whole tumor lysate, 54 or some combination of tumor antigens and cytokines. 55 Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific antigen commonly expressed by glioblastoma cells but not on normal tissue. 56 PEP-3 is a 14-amino-acid peptide from EGFRvIII, which, when coupled with a foreign ''helper molecule'' keyhole limpet hemocyanin (KLH) (PEP-3-KLH) has been used as a vaccine to generate EGFRvIIIspecific antibodies. 56, 57 Sampson et al 52, 58 have studied the EGFRvIII peptide, PEPvIII-KLH in 18 glioma patients expres-sing EGFRvIII on their tumors. The vaccinated patients had improved 6-month progression-free survival (the primary endpoint) and improved overall survival compared with contemporary controls. 58 Of interest, sampling of the tumor in some cases at recurrence revealed loss of EGFRvIII expression.
Although EGFR-related peptides have received the most attention, there are other peptides that are tumor associated which may be useful in inducing immune responses. Yajima et al 53 created ''personalized peptide vaccines.'' They treated 21 HLA-A2 or HLA-A24 patients with GBM with a combination of 23 to 25 tumor-associated peptides known to bind to either HLA-A2 or HLA-A24. Among them, 5 patients had a partial response, 8 patients had stable disease, and 8 patients had progressive disease. Peptide-specific IgG antibody responses were detected in the tumor bed or spinal fluid of all patients tested.
Terasaki et al also explored this idea of ''antigen soup'' as a peptide-immunotherapy approach. 59 They enrolled 12 HLA-A24Ypositive patients with glioblastoma and HLA-A24. The patients were vaccinated with HLA-A24Yrestricted (ITK-1) peptides. ITK-1 consisted of 14 peptides known to be expressed at high levels in cancer cells and low levels in normal cells. The 14 chosen peptides were capable of inducing peptide-specific cellular immunity and humoral immunity in HLA-A24 patients with glioblastoma. Of the 12 patients enrolled, 2 patients had a partial clinical response, 5 had stable disease, and 5 had progressive disease. All patients tolerated the vaccination without any serious adverse reactions. 59 Another approach being explored is to vaccinate with a heat shock protein in complex with autologous tumor derived peptides. Clinical trials in patients with recurrent glioblastoma have revealed both an adaptive and innate immune response with the treatment being well tolerated and suggesting an improvement in survival when compared with historic controls. 60 It is unclear if individual peptides or whole tumor lysate induce a better immune response, as they have never been studied head to head. Autologous tumor-prepared vaccines alone or in combination with cytokines have also demonstrated isolated clinical response. 54, 55 Because DCs are critical in initiating antigen-specific immunity, we and others have used autologous DC vaccination as an approach to treat patients with glioblastoma. The basic strategy for DC vaccination is to give autologous DCs, which have been manipulated ex vivo to present autologous tumor antigens. 53 ,61Y65 DC administration has varied by route (intradermal, subcutaneous, intranodal, intratumoral), schedule, and combination with other treatment modalities. 66 Most trials are phase I studies that included patients with recurrent high-grade gliomas (variable number of glioblastomas), and in general, vaccination with DCs has been well tolerated. 62Y64,67Y71 Some studies have been able to show clinical responses, either in tumor regression 61, 65, 70, 71 or improved survival compared with historical or contemporary controls. 71, 72, 74 Immune responses have also been demonstrated with use of surrogate endpoints. In patients who underwent reoperation after vaccination with DCs, some have infiltration of CTL within the tumor. 62, 67, 68 Some studies enrolled patients with both recurrent and newly diagnosed glioblastoma, but recent series have included patients with newly diagnosed glioblastoma and in combination with other therapeutic modalities (Table 1) . 31 ,66Y68,72Y75 As can be seen in Table 1 , of the 73 patients with newly diagnosed glioblastoma treated with DCs immune therapy as part of the first-line therapy, only 2 developed severe toxicity including 1 report of a patient who developed a cutaneous glioblastoma at a lymph node injection site. 72 One additional high-grade toxicity was seen in the 156 patients with recurrent glioblastoma treated with DC vaccines ( Table 2) .
We evaluated the immunologic response to cervical intranodal vaccination with autologous tumor lysate-loaded DCs in 10 patients with newly diagnosed glioblastoma after concomitant radiation therapy and chemotherapy and before starting adjuvant temozolomide 31 (Fig. 4) . We explored immunologic endpoints in a novel approach using hierarchical clustering analysis of the results of 5 immune assays measured before and after vaccination ( Fig. 5 ). Immune activation as determined by this methodology was associated with improved survival.
Other approaches to vaccine therapy deserve mention. In 2001, Schneider et al 76 were able to deliver autologous tumor cells via a viral vaccine vector using Newcastle disease virus (NDV). The advantage of NDV is that it is a single-stranded RNA virus that poses little health hazard to humans and has the ability to selectively kill human tumor cells. Other approaches include use of autologous tumor transfected with cytokine genes to express cytokine or DCYtumor cell fusions. 77, 78 To date, all vaccine and immune therapy studies in patients with glioblastoma including ours suffer from small sample size and thus bias induced by patient selection. There are many variables in the design of the studies without consensus in the optimal method to prepare and condition the DCs, antigen to use, site of administration, and immune assays to monitor. 79 A careful clinical trial design that would provide information on the most favorable dose, frequency of administration, and timing to introduce DC-based vaccine in the multimodality treatment scheme of patients with glioblastoma is needed. Nevertheless, the observations of induction of tumor-specific immune responses, clinical response, prolonged survival in a few patients, and low toxicity are encouraging and support the continued investigation of immune therapies in patients with glioblastoma.
END POINTS AND OUTCOMES
Although primary endpoints of overall survival and progression-free survival are most important in the development of a new therapy, surrogate endpoints can be very helpful in predicting clinical outcomes and fueling further research. Surrogate endpoints for vaccine therapy include a variety of immune responses. 5 Often reported are delayed-type hypersensitivity responses, interferon F (IFNF) release from peripheral blood mononuclear cells as measured by flow cytometry, or IFNF enzyme-linked immunosorbent spot (ELISPOT) assays. Delayed-type hypersensitivity reactions are used as a measure of antigen recall and correlate with peripheral blood antigenspecific T-cell responses. 80, 81 Nevertheless, patients with glioblastoma are frequently anergic, and it is of limited use for monitoring these patients. 31, 72 IFNF is released by type I CD4+ T cells. 80 The IFNF ELISPOT assay is one of the common methods of assessing adaptive immune responses. Recent studies have reported a positive correlation between immune response, measured by ELISPOT assays, and clinical outcomes. 80 We have used the dye dilution proliferation assay (DDPA) in immunotherapy clinical trials to evaluate immune response by monitoring tumor-specific CD8+ and CD4+ precursor frequency. 82 This method also allows measurement of the proportion of CD4+ and CD8+ IFN-producing cells for immune monitoring. The median values for the results of 5 immune response measurements (DDPA and ELISPOT) before and after DC-based vaccination in 10 patients with glioblastoma were analyzed using hierarchical clustering analysis. 31 A measurable immune response by this composite method was associated with improved survival. There is need to standardize and prospectively validate immune-monitoring assays if immunologic surrogate endpoints are to be used in larger clinical trials involving multiple sites.
Radiologic assessment by magnetic resonance imaging (MRI) has been the mainstay in the evaluation of the response to therapy in glioblastoma and used as the primary endpoint in many phase II trials. The appearance of new and more varied oncological treatment modalities has underscored the limitations of the criteria used to assess response in clinical trials. 83 Specifically, in immune therapy trials for high-grade gliomas, increased size of gadolinium-enhanced lesions on MRI studies, suggestive of recurrent tumor, have revealed inflammatory infiltration without active tumor. 84 Furthermore, the modest response on MRI does not correlate with clinical endpoints. 85 Therefore, radiologic criteria to evaluate brain tumor immunotherapy have to be refined. and the use of more advanced techniques to image inflammation and immune response is needed. 86 
FUTURE DIRECTIONS
The challenges of the future of immune therapies relate to enhancing antigen presentation capabilities, effectively breaking tumor-induced immune tolerance, improving activation of tumor-specific cytolytic effector cells, and the standardization and upscale production of cell-based therapy. At the same time, there is concern that further boosting of the immune response, albeit more effective, may result in serious adverse events secondary to brain edema and autoimmunity.
A strong and long-lasting anti-tumor T-cell response that confers clinical benefit is the goal on DC-based immunotherapy. Enhancing the APC capabilities by polarizing the cell toward a more effective (>-type) 1 DC phenotype has been reported, but there is still controversy on the culture conditions to obtain the most activated and potent DCs. A clinical trial examined using the fusion of dendritic and glioma cells combined with recombinant human interleukin 12 for the treatment of malignant glioma. 65 No serious adverse effects and a few responses on MRI were observed. The combination of DC vaccination with an immunoadjuvant polyinosinicY polycytidylic acid (poly[I/C]) stabilized by lysine and carboxymethylcellulose (poly-ICLC), a PAMP that activates DCs, was safe. 84 Finally, the optimal route of administration of DCs for brain tumors has not been established, although animal 87 and clinical studies 88 suggest that intranodal injection is the most effective.
One of the challenges with vaccine therapy is the selfimposed ''brake'' on the immune system in glioma patients, which may limit the immune system's response to a vaccine. There are a few potential targets that could remove the brake of the immune system. One strategy might be to deplete the regulatory T cells. To that end, an antibody against CD4 or CD25 could be used to target Tregs, or more general immunotoxins could be used. A study suggests that administration of daclizu-mab, an antibody against IL-2R>, when patients are lymphopenic after administration of temozolomide enhances the antitumor immunity of vaccination by depleting Treg. Once T cells are activated, they up-regulate molecules such as CTLA4 and PD-1 to limit their activity (Fig. 6 ). Use of blocking humanized monoclonal antibodies such as ipilimumab (anti-CTLA4) to these checkpoint molecules seems very promising and has already made it to the clinic in treating patients with metastatic melanoma. 89 A phase I clinical trial using a vaccine composed of autologous tumor cells genetically modified by a TGF-A2 antisense vector in 6 patients with recurrent glioblastoma was well tolerated with the indication of anti-tumor-induced immunity. 90 Use of additional inflammatory cytokines such as IL-12, IL-7, and IL-15; activating antibodies to costimulatory molecules such as CD40; or blocking antibodies to immune inhibitory cytokines such as IL-10 or TGF-A in combination with DC vaccination can potentially enhance clinical activity. 91 Which of these strategies in combination with vaccination will yield the best therapeutic ratio (most effective and less toxic) is to be determined. Treatment for high-grade glioma involves a multidisciplinary approach using surgery, radiation therapy, and chemotherapy. Clarifying when and how immune therapy should be given with these other modalities and the role of steroid use in this population of patients will require a well-designed and appropriately powered clinical trial. In small studies, we and others have demonstrated that DC vaccines can be given safely to patients with glioblastoma undergoing temozolomide chemotherapy alone or in combination with radiotherapy. 31 The studies confirm that tumor-specific immune responses in these patients can be induced. 31, 58, 69, 75 The rationale to give chemotherapy with immunotherapy may relate to the chemotherapy's effects on tumor release of relevant antigens, on inhibiting the regulatory compartment, and on the ability to change the tumor vasculature providing better access for effector cells. 68,92Y94 Another possibility is that vaccination sensitizes the tumor to chemotherapy. 72, 92, 94 
CONCLUSIONS
Research during the last 10 years has demonstrated that immune therapy for glioblastoma triggers a measurable immune response despite poor tumor antigenicity and considerable immune suppression. If that anti-tumor effect is enough to translate in improvement in survival is still to be proven. The limited number of patients with glioblastoma, the lack of a cooperative group that can do large clinical trials for the study of brain tumor immunotherapy, and the variability in approaches and immune-monitoring assays used are the major barriers to determine if immune therapy could be part of the standard of care. Furthermore, the challenge of immunotherapy is to understand the various regulatory and costimulatory factors in the patient and the tumor microenvironment and being able to manipulate these forces effectively to enhance anti-tumor immune response and clinical benefit. As immunotherapy evolves, prognostic and predictive biomarkers will be important to determine which patients will make the best candidates for vaccine therapies. There is a need for harmonization and validation of immunologic endpoints as well as imaging techniques that allow adequate monitoring of patients with brain tumors receiving immune base therapies. With our expanded knowledge of immune pathways and the effects tumors have on immune function, we will be better able to develop vaccine strategies for the future.
